Enhancing the effectiveness of radioiodine treatment for thyroid cancer
Improving efficacy of radioiodine treatment of thyroid cancer
This study is looking at how to make radioiodine therapy work better for people with advanced thyroid cancer who haven't had much success with other treatments, by adding special medications that might help the cancer cells absorb the iodine more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11051244 on NIH RePORTER |
What this research studies
This research focuses on improving the effectiveness of radioiodine therapy for patients with advanced thyroid cancer who do not respond well to current treatments. It investigates the role of specific inhibitors that target signaling pathways involved in cancer cell resistance to therapy. By combining these inhibitors with radioiodine treatment, the research aims to enhance the uptake and retention of iodine in cancerous thyroid cells, potentially leading to better treatment outcomes. The study will involve clinical trials to assess the impact of these combined therapies on patients with specific genetic mutations associated with thyroid cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced thyroid cancer, particularly those with BRAFV600E mutations who have not responded to standard radioiodine therapy.
Not a fit: Patients with early-stage thyroid cancer or those who respond well to existing radioiodine treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for patients with radioiodine-refractory thyroid cancer.
How similar studies have performed: Previous studies have shown promise in using targeted inhibitors to enhance the effectiveness of cancer therapies, indicating potential for success in this approach.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Fagin, James a — Sloan-Kettering Inst Can Research
- Study coordinator: Fagin, James a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.